3 results
Approved WMOPending
To establish the preferred treatment of AIN to prevent the development of severe anal neoplasia (persistent AIN III or anal carcinoma) in HIV+ MSM and HIV+ woman.
Approved WMOCompleted
To demonstrate that Nanocort is safe and effectively reduces the inflammatory signs and symptoms of active GO.
Approved WMOPending
Main Phase:To demonstrate the superiority of medium-dose BDP/FF/GB pMDI compared to high-dose BDP/FF pMDI in terms of the proportion of subjects exhibiting on average NPAL over 26 weeks of treatment in the study sub-population with PAL at screening…